Financial PerformanceAnalyst reduces sales and profit estimates by approximately 2% due to a slow start to the year, indicating potential disappointment in upcoming financial results.
Foreign Exchange And Interest RatesSpirax faces currency headwinds and higher interest rates, leading to a guided negative impact on sales and EBITA, suggesting downward pressure on future earnings.
Valuation ConcernsSpirax's high valuation metrics, trading at 19x 2024e EV/EBITDA and 31x PE, could deter investors as it remains the most expensive stock in analyst coverage.